The multi-agentic AI platform delivers personalised therapy optimisation and investment risk assessment
GNQ Insilico (GNQ), a TechBio firm leveraging exponential technologies for precision medicine, launched its deep tech Drug Assessment Platform (DAP). This system combines artificial intelligence with a proprietary pathways-driven multi-omics engine to change how therapies are evaluated, optimised, and personalised for patients.
The DAP is available for deployment across healthcare, pharmaceutical companies and life sciences investors. The platform offers flexible deployment options and support for integration into existing clinical and research workflows.
GNQ's chief executive officer, Rehan Huda, has been chosen as a guest speaker on a panel at the RESI Boston Conference on September 17, 2025. The panel, “AI-Driven Transformation in Life Sciences: Biopharma, Big Pharma, and Investor Perspectives”, will focus on how AI is reshaping the landscape of drug discovery, development and commercialisation.
Assessments and enhancements
The DAP has shown its potential through assessments and enhancements across multiple therapeutic interventions, including:
- p53 agonist-based combination therapy for enhanced lung cancer treatment
- Proprietary combination therapy using protein assembly modulators for ALS
- Optimised treatment protocols for a traumatic brain injury study conducted for a major sports league
- Multiple myeloma therapy optimisation
Built on GNQ’s proprietary multi-omics engine containing tens of millions of networked connections, based on human biological pathways and insights from the latest research, the DAP employs AI agents that apply these insights to therapeutic assessments.
Dr. Jerome Schentag, chief operating officer, said, “Having been utilised to assess the potential for combining p53 agonists with targeted therapies in lung cancer treatment, it is clear that the DAP will have a transformative impact on therapeutic development. The platform's ability to identify synergistic combinations and predict patient-specific responses has already shown remarkable promise in the initial applications. Because the platform allows actionable information to be available to the clinician in a matter of days, the DAP offers a fundamental advancement in our ability to personalise cancer therapy and optimise treatment outcomes while minimising adverse effects. The implications for both patient care and pharmaceutical development are profound.”
AI
The DAP delivers capabilities in therapeutic evaluation and optimisation:
Prescriptive AI predicts and enhances therapy efficacy across diverse patient profiles, predicts toxicity responses, and identifies optimal patient populations for specific treatments.
Causal AI optimisation uses a causal inference engine combined with real-world data, suggests personalised dosage regimens, and optimises therapy by recommending additional compounds to the original formulation.
Investment risk assessment helps to de-risk investments at the early stages of drug development, differentiate promising candidates from ineffective compounds, and validate therapeutic potential before clinical trials.
Sudhir Saxena, chief technology officer, said, "The launch of our Drug Assessment Platform represents a paradigm shift in how we approach precision medicine and drug development. By harnessing the power of our comprehensive systems biology pathways-driven proprietary engine with advanced AI agents, we are able to predict therapeutic outcomes with unprecedented accuracy. This platform doesn't just analyse data—it understands the complex interplay of biological pathways, genetic variants, and therapeutic interventions to deliver truly personalised treatment strategies. We are essentially bringing the power of quantum-level biological understanding to clinical decision-making."
Market Impact
The platform addresses critical challenges across the healthcare and pharmaceutical ecosystem:
For investors, proprietary systems biology models enable conducting scientific due diligence on life sciences companies' therapeutic candidates, provide recommendations for de-risking investment decisions, and facilitate a paradigm shift in portfolio optimisation.
For pharmaceutical companies, key areas of focus include early-stage compound evaluation and validation, enhancing target therapies to improve efficacy/safety outcomes, and refining clinical trial design and patient selection.
For healthcare providers, personalised treatment selection and optimisation, reduced trial-and-error prescribing, improved patient outcomes and safety profiles, and cost-effective therapeutic decisions.
